Year |
Citation |
Score |
2021 |
Beaulieu WT, Panaccione DG, Quach QN, Smoot KL, Clay K. Diversification of ergot alkaloids and heritable fungal symbionts in morning glories. Communications Biology. 4: 1362. PMID 34873267 DOI: 10.1038/s42003-021-02870-z |
0.519 |
|
2020 |
Glassman AR, Wells JA, Josic K, Maguire MG, Antoszyk AN, Baker C, Beaulieu WT, Elman MJ, Jampol LM, Sun JK. Five-Year Outcomes after Initial Aflibercept, Bevacizumab, or Ranibizumab Treatment for Diabetic Macular Edema (Protocol TÂ Extension Study). Ophthalmology. PMID 32402554 DOI: 10.1016/J.Ophtha.2020.03.021 |
0.318 |
|
2020 |
Glassman AR, Baker CW, Beaulieu WT, Bressler NM, Punjabi OS, Stockdale CR, Wykoff CC, Jampol LM, Sun JK. Assessment of the DRCR Retina Network Approach to Management With Initial Observation for Eyes With Center-Involved Diabetic Macular Edema and Good Visual Acuity: A Secondary Analysis of a Randomized Clinical Trial. Jama Ophthalmology. PMID 32077907 DOI: 10.1001/Jamaophthalmol.2019.6035 |
0.311 |
|
2019 |
Bressler NM, Beaulieu WT, Bressler SB, Glassman AR, Melia BM, Jampol LM, Jhaveri CD, Salehi-Had H, Velez G, Sun JK. ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY AND RISK OF TRACTION RETINAL DETACHMENT IN EYES WITH PROLIFERATIVE DIABETIC RETINOPATHY: Pooled Analysis of Five DRCR Retina Network Randomized Clinical Trials. Retina (Philadelphia, Pa.). PMID 31567817 DOI: 10.1097/Iae.0000000000002633 |
0.309 |
|
2019 |
Baker CW, Glassman AR, Beaulieu WT, Antoszyk AN, Browning DJ, Chalam KV, Grover S, Jampol LM, Jhaveri CD, Melia M, Stockdale CR, Martin DF, Sun JK. Effect of Initial Management With Aflibercept vs Laser Photocoagulation vs Observation on Vision Loss Among Patients With Diabetic Macular Edema Involving the Center of the Macula and Good Visual Acuity: A Randomized Clinical Trial. Jama. PMID 31037289 DOI: 10.1001/Jama.2019.5790 |
0.301 |
|
2019 |
Bressler SB, Beaulieu WT, Glassman AR, Gross JG, Melia M, Chen E, Pavlica MR, Jampol LM. PHOTOCOAGULATION VERSUS RANIBIZUMAB FOR PROLIFERATIVE DIABETIC RETINOPATHY: Should Baseline Characteristics Affect Choice of Treatment? Retina (Philadelphia, Pa.). PMID 30807516 DOI: 10.1097/Iae.0000000000002377 |
0.324 |
|
2018 |
Sun JK, Glassman AR, Beaulieu WT, Stockdale CR, Bressler NM, Flaxel C, Gross JG, Shami M, Jampol LM. Rationale and Application of the Protocol S Anti-Vascular Endothelial Growth Factor Algorithm for Proliferative Diabetic Retinopathy. Ophthalmology. PMID 30096354 DOI: 10.1016/J.Ophtha.2018.08.001 |
0.31 |
|
2018 |
Bressler NM, Beaulieu WT, Maguire MG, Glassman AR, Blinder KJ, Bressler SB, Gonzalez VH, Jampol LM, Melia M, Sun JK, Wells JA. Early Response to Anti-Vascular Endothelial Growth Factor and Two-Year Outcomes Among Eyes with Diabetic Macular Edema in Protocol T. American Journal of Ophthalmology. PMID 30077569 DOI: 10.1016/J.Ajo.2018.07.030 |
0.31 |
|
2018 |
Bressler SB, Beaulieu WT, Glassman AR, Gross JG, Melia M, Chen E, Pavlica MR, Jampol LM. Panretinal Photocoagulation Versus Ranibizumab for Proliferative Diabetic Retinopathy: Factors Associated with Vision and Edema Outcomes. Ophthalmology. PMID 29980333 DOI: 10.1016/J.Ophtha.2018.04.039 |
0.319 |
|
2018 |
Bressler NM, Beaulieu WT, Glassman AR, Blinder KJ, Bressler SB, Jampol LM, Melia M, Wells JA. Persistent Macular Thickening Following Intravitreous Aflibercept, Bevacizumab, or Ranibizumab for Central-Involved Diabetic Macular Edema With Vision Impairment: A Secondary Analysis of a Randomized Clinical Trial. Jama Ophthalmology. PMID 29392288 DOI: 10.1001/Jamaophthalmol.2017.6565 |
0.333 |
|
2017 |
Bressler SB, Beaulieu WT, Glassman AR, Gross JG, Jampol LM, Melia M, Peters MA, Rauser ME. Factors Associated with Worsening Proliferative Diabetic Retinopathy in Eyes Treated with Panretinal Photocoagulation or Ranibizumab. Ophthalmology. PMID 28161147 DOI: 10.1016/J.Ophtha.2016.12.005 |
0.306 |
|
2016 |
Beaulieu WT, Bressler NM, Melia M, Owsley C, Mein CE, Gross JG, Jampol LM, Glassman AR. Panretinal Photocoagulation versus Ranibizumab for Proliferative Diabetic Retinopathy: Patient-Centered Outcomes from a Randomized Clinical Trial. American Journal of Ophthalmology. PMID 27523491 DOI: 10.1016/J.Ajo.2016.08.008 |
0.303 |
|
2015 |
Beaulieu WT, Panaccione DG, Ryan KL, Kaonongbua W, Clay K. Phylogenetic and chemotypic diversity of Periglandula species in eight new morning glory hosts (Convolvulaceae). Mycologia. PMID 25977213 DOI: 10.3852/14-239 |
0.543 |
|
2014 |
Panaccione DG, Beaulieu WT, Cook D. Bioactive alkaloids in vertically transmitted fungal endophytes Functional Ecology. 28: 299-314. DOI: 10.1111/1365-2435.12076 |
0.396 |
|
2013 |
Beaulieu WT, Panaccione DG, Hazekamp CS, mckee MC, Ryan KL, Clay K. Differential allocation of seed-borne ergot alkaloids during early ontogeny of morning glories (Convolvulaceae). Journal of Chemical Ecology. 39: 919-30. PMID 23835852 DOI: 10.1007/S10886-013-0314-Z |
0.534 |
|
2013 |
Cook D, Beaulieu WT, Mott IW, Riet-Correa F, Gardner DR, Grum D, Pfister JA, Clay K, Marcolongo-Pereira C. Production of the alkaloid swainsonine by a fungal endosymbiont of the Ascomycete order Chaetothyriales in the host Ipomoea carnea. Journal of Agricultural and Food Chemistry. 61: 3797-803. PMID 23547913 DOI: 10.1021/Jf4008423 |
0.519 |
|
2012 |
Johnson DJ, Beaulieu WT, Bever JD, Clay K. Conspecific negative density dependence and forest diversity. Science (New York, N.Y.). 336: 904-7. PMID 22605774 DOI: 10.1126/Science.1220269 |
0.556 |
|
2012 |
Johnson DJ, Beaulieu WT, Bever JD, Clay K. Response to comment on "conspecific negative density dependence and forest diversity" Science. 338: 469-c. DOI: 10.1126/Science.1225996 |
0.522 |
|
2012 |
Johnson DJ, Beaulieu WT, Bever JD, Clay K. Conspecific negative density dependence and forest diversity Science. 336: 904-907. DOI: 10.1126/science.1220269 |
0.455 |
|
Show low-probability matches. |